Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927-35. doi:10.1200/JCO.2012.48.5052
Tickle TL, Segata N, Waldron L, Weingart U, Huttenhower C. Two-stage microbial community experimental design. ISME J. 2013;7(12):2330-9. doi:10.1038/ismej.2013.139
Tamborero D, Gonzalez-Perez A, Perez-Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650. doi:10.1038/srep02650
Ran A, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-308. doi:10.1038/nprot.2013.143
Batey L, Moon JE, Yu Y, et al. A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency. J Clin Endocrinol Metab. 2014;99(1):E153-9. doi:10.1210/jc.2013-3106
Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-7. doi:10.1126/science.1247005
Rosenbluh J, Wang X, Hahn WC. Genomic insights into WNT/β-catenin signaling. Trends Pharmacol Sci. 2014;35(2):103-9. doi:10.1016/j.tips.2013.11.007
Ibrahim-Verbaas CA, Fornage M, Bis JC, et al. Predicting stroke through genetic risk functions: the CHARGE Risk Score Project. Stroke. 2014;45(2):403-12. doi:10.1161/STROKEAHA.113.003044
Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506(7487):179-84. doi:10.1038/nature12929
Rees E, Kirov G, Sanders A, et al. Evidence that duplications of 22q11.2 protect against schizophrenia. Mol Psychiatry. 2014;19(1):37-40. doi:10.1038/mp.2013.156